Cell counts of each human hematopoietic lineage in bone marrow of hu-NOG mice
| Lineage . | Control, n = 5 . | IFN 10 μg/kg, n = 5 . | IFN 30 μg/kg, n = 5 . | IFN 30 μg/kg; NIP-004 30 mg/kg, n = 5 . |
|---|---|---|---|---|
| Total white blood cells, × 106 | 6.5 ± 0.5 | 3.9 ± 0.6 | 4.7 ± 0.7 | 5.4 ± 0.4 |
| Megakaryocytes, × 104 | 3.9 ± 0.5 | 4.7 ± 0.5 | 4.7 ± 0.5 | 8.2 ± 0.8*† |
| Myeloid cells, × 106 | 2.5 ± 0.3 | 0.9 ± 0.1* | 1.0 ± 0.1* | 2.0 ± 0.2 |
| Erythroblasts, × 104 | 6.9 ± 1.5 | 1.1 ± 0.5* | 0.2 ± 0.1* | 0.3 ± 0.1* |
| Progenitor cells, × 105 | 3.2 ± 0.9 | 3.1 ± 0.5 | 3.9 ± 0.8 | 4.4 ± 0.3 |
| B cells, × 106 | 3.2 ± 0.3 | 2.2 ± 0.4 | 3.0 ± 0.7 | 2.2 ± 0.2 |
| T cells, × 105 | 2.6 ± 0.2 | 1.6 ± 0.2 | 1.3 ± 0.3 | 1.8 ± 0.2 |
| Lineage . | Control, n = 5 . | IFN 10 μg/kg, n = 5 . | IFN 30 μg/kg, n = 5 . | IFN 30 μg/kg; NIP-004 30 mg/kg, n = 5 . |
|---|---|---|---|---|
| Total white blood cells, × 106 | 6.5 ± 0.5 | 3.9 ± 0.6 | 4.7 ± 0.7 | 5.4 ± 0.4 |
| Megakaryocytes, × 104 | 3.9 ± 0.5 | 4.7 ± 0.5 | 4.7 ± 0.5 | 8.2 ± 0.8*† |
| Myeloid cells, × 106 | 2.5 ± 0.3 | 0.9 ± 0.1* | 1.0 ± 0.1* | 2.0 ± 0.2 |
| Erythroblasts, × 104 | 6.9 ± 1.5 | 1.1 ± 0.5* | 0.2 ± 0.1* | 0.3 ± 0.1* |
| Progenitor cells, × 105 | 3.2 ± 0.9 | 3.1 ± 0.5 | 3.9 ± 0.8 | 4.4 ± 0.3 |
| B cells, × 106 | 3.2 ± 0.3 | 2.2 ± 0.4 | 3.0 ± 0.7 | 2.2 ± 0.2 |
| T cells, × 105 | 2.6 ± 0.2 | 1.6 ± 0.2 | 1.3 ± 0.3 | 1.8 ± 0.2 |
Data are means (± SEM) of cells/femur for 5 mice. Bone marrow cells were collected from the femurs of NOG mice transplanted with human umbilical cord blood–derived CD34+ cells (hu-NOG). The number in each cell lineage was measured by flow cytometry using lineage-specific antibodies and Flow-Count Fluorospheres. PEG-IFN-α 2b and NIP-004 were administered using the same protocol as described in Figure 4. Each lineage-specific marker was indicated as follows: total white blood cells, CD45+; megakaryocytes, CD41+; myeloid cells, CD45+CD33+; erythroblasts, CD45−CD71+GPA+; progenitor cells, CD45+CD34+; B cells, CD45+CD38+CD19+; T cells, CD45+CD38−CD3+.
P< .01 versus control.
P< .01 versus PEG-IFN-α 2b 30 μg/kg single treatment.